TITLE

Hormone replacement therapy, heart disease and breast cancer

PUB. DATE
September 1997
SOURCE
CMAJ: Canadian Medical Association Journal;09/15/97, Vol. 157 Issue 6, p635
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on data from the Nurses' Health Study on the largest study so far of the effects of hormone replacement therapy after menopause. The confirmation of existing evidence on heart disease and breast cancer; Support for individualized decision making on treatment; The numbers of women studied; The benefits and risks.
ACCESSION #
9709234656

 

Related Articles

  • HRT trial.  // New Scientist;12/17/94, Vol. 144 Issue 1956, p12 

    Reports on Great Britain's plan to recruit 23,000 women to find out the effectivity of hormone replacement therapy (HRT). Pending approval of funding; Cost of trial for 25 years; Funding pledges from the British Heart Foundation and the pharmaceuticals industry.

  • FDA getting tougher on hormone replacement. Dickinson, James G. // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p27 

    Reports on the decision of the Food and Drug Administration to increase safety studies on hormone replacement therapy (HRT) products in the U.S. Assessment of the efficacy of the drugs; Analysis on the side effects of the product; Expansion of the trial period.

  • Health check. Snyderman, Nancy // Good Housekeeping;Mar97, Vol. 224 Issue 3, p70 

    Presents information concerning health. Discussion on the causes of food allergies; Information on ThinPrep, a kind of pap test; Hormone therapy that provides the protection without the side effects of estrogen.

  • Controversies in Women's Health Maintenance. Morrison, Elizabeth H. // American Family Physician;3/1/1997, Vol. 55 Issue 4, p1283 

    Focuses on which preventive and screening measures should be recommended to female patients, in light of cost-consciousness. Disagreement on how often the papanicolaou test (pap smear) should be done; Consensus on the effectiveness of regular test as a means of screening; Concerns expressed...

  • HRT for Alzheimer's?  // Patient Care;8/15/1996, Vol. 30 Issue 13, p13 

    Reports on the Women's Health Initiative Memory Study's exploration of the use of hormone replacement therapy to prevent memory loss. Preliminary data indicating delay in the onset of symptoms of Alzheimer's disease through hormone therapy; Participants exclude those who were already diagnosed...

  • Does HRT preserve memory and attention?  // Contemporary OB/GYN;May2002, Vol. 47 Issue 5, p40 

    Discusses research being done on the association of long-term estrogen replacement with improved non-verbal memory and attentional measures in postmenopausal women. Reference to a study by Y. R. Smith et al., published in a 2001 issue of the journal "Fertil Steril"; Tests given to the...

  • Are biannual Papanicolaou (Pap) tests useful in postmenopausal women? Does hormone replacement therapy (HRT) affect the development of cervical cytology abnormalities? Nguyen, David; Church, Lili // Journal of Family Practice;Apr2001, Vol. 50 Issue 4, p368 

    The article discusses research done on the effect of Papanicolaou (Pap) tests and hormone replacement therapy (HRT) in postmenopausal women. The study aims to calculate the incidence of cytologic abnormalities and to evaluate the effect of HRT. A total of 2,561 women younger than 80 years were...

  • What is the best diagnostic approach to postmenopausal vaginal bleeding in women taking hormone replacement therapy? Kerns, J. William; Mabry, Sandi; Lopez, Ricardo // Journal of Family Practice;Oct2001, Vol. 50 Issue 10, p843 

    The article discusses the diagnostic approach to post-menopausal vaginal bleeding in women who are on standard estrogen or progestin hormone replacement therapy (HRT). Since cervical abnormalities are not uncommon, women who have vaginal bleeding and are taking HRT should have a Pap test....

  • Testosterone-Topical Fortigel – Cellegy: Fortigel, Tostrex. Limited, Adis International // BioDrugs;2003, Vol. 17 Issue 4, p299 

    Cellegy Pharmaceuticals in the US is developing a topical gel formulation of testosterone replacement therapy [Tostrexâ„¢, Fortigelâ„¢] for men, based on the company's proprietary Permeate technology. The new gel formulation, containing 2% testosterone, is intended to be a more...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics